Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)

NCT02753530 is registered in ClinicalTrials.gov with ZevraDenmark as lead sponsor.

NCT NCT02753530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02753530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)
Lead sponsor
ZevraDenmark
Phase
Phase 2
Overall status
Completed
Start date
August 16, 2017
Completion date
January 11, 2021
Enrollment
152 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

inclusion body myositis